Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians
DOI: 10.1055/s-0043-1771241
Original Article

Expression of PD-L1 in Malignant Soft Tissue Neoplasm and Their Correlation with Clinicopathological Parameters

Ashutosh Mishra
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Anurag Singh
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Madhu Kumar
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Mala Sagar
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Malti Kumari
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Sumaira Qayoom
1   Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Vijay Kumar
2   Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India
› Author Affiliations
Fuding No funding and not a part of the employment of the authors.
› Further Information
Also available at
  Permissions and Reprints

Abstract

Objectives Programmed death ligand-1 (PD-L1) expression in malignant epithelial neoplasms has been the subject of numerous studies; however, less data on its application to sarcomas are available. This research focused on the expression of PD-L1 and how it correlated with clinicopathological characteristics in soft tissue sarcomas.

Materials and Methods The anti-PD-L1 antibody and Ki-67 were stained in 50 cases of sarcoma that had been confirmed by biopsy and immunohistochemistry. The tumor cell percentage with complete or incomplete membrane staining was calculated. Sarcomas were categorized as positive (>1% of tumor cells with complete or incomplete membrane staining) or negative (≤1% of tumor cells with complete or incomplete membrane staining). The data were analyzed using statistical package for Social Sciences version 21.0.

Results The soft tissue sarcomas showing marked pleomorphic morphology were significantly linked to positive PD-L1 expression than other subtypes of sarcomas (p = 0.042). Proliferation index grade III accounts for 62.5% of cases with positive PD-L1 expression, followed by proliferation index grade II with 25% cases and grade I with 12.5% cases. On comparing statistically, this difference was found to be significant (p = 0.013). A significant association was found between PD-L1 expression and the poor outcome of follow-up (p = 0.024).

Conclusion Our study showed a significant relationship between malignant soft tissue tumor positivity for PD-L1 and pleomorphic morphology, a higher proliferation index grade, and a poorer prognosis.

Keywords

PD-L1 - immunohistochemistry - sarcomas - immunotherapy - immune checkpoint inhibitors

Authors' Contribution

A.M. did a literature search, data acquisition, conceptual analysis, and proof correction. A.S. did conceptual analysis, study designing, literature search, and manuscript writing. M.K. did data analysis and designing. M.S. did data analysis, study designing, and proofreading. M.K. did conceptual analysis and data acquisition. S.Q. did literature search and proof reading. V.K. contributed to clinical studies, literature search and critical appraisal.


Ethical Approval

The study is approved by the Research Ethics Committee of King George's Medical University Lucknow (97th ECM IIB-Thesis/P37, Letter number 1717/Ethics/19).




Publication History

Article published online:
28 July 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sbaraglia M, Dei Tos AP. The pathology of soft tissue sarcomas. Radiol Med (Torino) 2019; 124 (04) 266-281
    CrossrefPubMedSearch in Google Scholar
  • 2 Guan J, Lim KS, Mekhail T, Chang CC. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med 2017; 141 (06) 851-861
    CrossrefPubMedSearch in Google Scholar
  • 3 Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14 (04) 847-856
    CrossrefPubMedSearch in Google Scholar
  • 4 Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry: friend or foe?. Arch Pathol Lab Med 2016; 140 (04) 326-331
    CrossrefPubMedSearch in Google Scholar
  • 5 Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist 2017; 22 (01) 81-88
    CrossrefPubMedSearch in Google Scholar
  • 6 Qu J, Mei Q, Liu L. et al. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol 2021; 13: 1758835921992968
    CrossrefPubMedSearch in Google Scholar
  • 7 Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther 2019; 194: 84-106
    CrossrefPubMedSearch in Google Scholar
  • 8 Cunningham CR, Dodd L, Esebua M, Layfield LJ. PD-L1 expression in sarcomas: an immunohistochemical study and review of the literature. Ann Diagn Pathol 2021; 55: 151823
    CrossrefPubMedSearch in Google Scholar
  • 9 Kelany M, Barth TF, Salem D, Shakweer MM. Prevalence and prognostic implications of PD-L1 expression in soft tissue sarcomas. Pathol Oncol Res 2021; 27: 1609804
    CrossrefPubMedSearch in Google Scholar
  • 10 Park HK, Kim M, Sung M, Lee SE, Kim YJ, Choi YL. Status of programmed death-ligand 1 expression in sarcomas. J Transl Med 2018; 16 (01) 303
    CrossrefPubMedSearch in Google Scholar
  • 11 Kim C, Kim EK, Jung H. et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 2016; 16 (01) 434
    CrossrefPubMedSearch in Google Scholar
  • 12 Bertucci F, Finetti P, Perrot D. et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology 2017; 6 (03) e1278100
    CrossrefPubMedSearch in Google Scholar
  • 13 D'Angelo SP, Shoushtari AN, Agaram NP. et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015; 46 (03) 357-365
    CrossrefPubMedSearch in Google Scholar
  • 14 Orth MF, Buecklein VL, Kampmann E. et al. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunology, Immunotherapy 2020; 69: 1353-1362
    CrossrefPubMedSearch in Google Scholar
  • 15 Vijayasankar S, Muralitharan S, Thanka J. Significance of Ki-67 in prognostication of soft tissue tumors. Ann Pathol Lab Med 2017; 4 (05) A579-A584
    CrossrefSearch in Google Scholar
  • 16 Granier C, De Guillebon E, Blanc C. et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2017; 2 (02) e000213
    CrossrefPubMedSearch in Google Scholar
  • 17 Alsaab HO, Sau S, Alzhrani R. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017; 8: 561
    CrossrefPubMedSearch in Google Scholar
  • 18 Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer 2019; 18 (01) 146
    CrossrefPubMedSearch in Google Scholar
  • 19 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182 (03) 311-322
    CrossrefPubMedSearch in Google Scholar
  • 20 Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 2015; 11 (03) 1566-1572
    CrossrefPubMedSearch in Google Scholar
  • 21 Ciancio N, Galasso MG, Campisi R, Bivona L, Migliore M, Di Maria GU. Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med 2012; 7 (01) 29
    CrossrefPubMedSearch in Google Scholar
  • 22 Que Y, Xiao W, Guan YX. et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer 2017; 8 (11) 2018-2025
    CrossrefPubMedSearch in Google Scholar
  • 23 Kösemehmetoğlu K, Özoğul E, Babaoğlu B, Tezel GG, Gedikoğlu G. Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors. Turk Patoloji Derg 2017; 1 (01) 192-197
    PubMedSearch in Google Scholar
  • 24 Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 2016; 33 (08) 93
    CrossrefPubMedSearch in Google Scholar
  • 25 Boxberg M, Steiger K, Lenze U. et al. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. OncoImmunology 2017; 7 (03) e1389366
    CrossrefPubMedSearch in Google Scholar
  • 26 Mohamed Mostafa AM, Gaballah AM, Kelany MR, Sayed F. Ki-67 expression and clinicopathological features of sarcomas. Pan Arab J Oncol 2019; 12 (03) 37-42
    Search in Google Scholar
  • 27 Ueda T, Aozasa K, Tsujimoto M. et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63 (08) 1607-1611
    CrossrefPubMedSearch in Google Scholar
  • 28 Choong PF, Akerman M, Willén H. et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation–a marker of metastasis?. Acta Pathol Microbiol Scand Suppl 1994; 102 (12) 915-924
    CrossrefPubMedSearch in Google Scholar